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Interleukin 6 (IL-6) is a multifunctional cytokine
with important roles in the acute phase response,1,2
haematopoesis3 and multiple aspects of immune regu-
lation.4 IL-6 also has roles as an autocrine stimulator of
growth in a number of tumours (most notably plasma-
cytomas and myelomas)5,6 as well as for some normal
cell types; it is inducible by poly(I).poly(C),7 and has a
number of functions in the endocrine and nervous sys-
tems. It has been suggested that it acts as a long range
alarm signal in the body. In line with these functions, it
has previously been known as B-cell stimulatory factor
2 (BSF-2), interferon β2 (IFN-β2), hepatocyte stimula-
tory factor (HSF)m 26 kD protein and hybridoma plas-
macytoma growth factor (HPGF). Over-expression of
IL-6 is known to be an important feature of the 
pathogenesis of a number of inflammatory diseases
such as rheumatoid arthritis, glomerula nephritis 
and psoriasis, as well as the development of myeloma/
plasmacytoma development. It may also be important
in the development of pathology in a number of 
infectious diseases such as mycobacterial disease and
AIDS.
IL-6 in the human is a 184 amino acid protein which
is processed from a 212 amino acid preprotein. It is vari-
ably glycosylated and phosphorylated. The main tran-
script is 1.3 kb, although 2 further downstream
polyadenylation sites have been mapped. Although the
promoter regions of IL-6 genes are closely conserved
between mouse and human, the structural sequences of
the gene are less well conserved (42% at the amino acid
level). Nonetheless, human IL-6 is able to support the
growth of murine IL-6 dependent myeloma lines.
In order to study whether IL-6 mediates the patho-
genesis of lentiviral disease in ruminants, we have
cloned, sequenced and expressed in a yeast based sys-
tem the structural regions of the ovine IL-6. Biological
assays on the product show that there is a species bar-
rier which prevents ovine IL-6 from supporting growth
of murine IL-6 dependent cell lines, and similarly that
human IL-6 is not recognized by ovine B-cells.
RESULTS
Cloning and sequence of ovine IL-6
To obtain the ovine IL-6 proprotein coding
sequence, single stranded cDNA was made from total
RNA of LPS stimulated alveolar macrophages and
amplified using the polymerase chain reaction with
primers derived from conserved regions of the 59 and
39 untranslated regions of IL-6 mRNA’s of human and
mouse. The product of this reaction was cloned into
pTZ18R and sequenced (Fig. 1B). The derived
sequence contains an open reading frame of 624 bp,
which encodes a protein of predicted Mr 5 23 429. This
protein is 53% identical to human IL-6 in sequence, and
43% identical to mouse IL-6. By analogy with the
known maturation pattern of human IL-6 it is likely that
the mature ovine protein is cleaved from the pro-pro-
tein at the proline at position 29. A predicted N-linked
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glycosylation site at amino acid position 38 is conserved
in the bovine sequence but not in other sequenced IL-
6 proteins.
Expression of ovine IL-6 in yeast
The same CDNA population was used as a sub-
strate to amplify an expression cassette containing this
open reading frame. This cassette was cloned into
pTZ18R, and subsequently into the galactose inducible
yeast Ty expression vector pOGS40. After resequenc-
ing, the resulting plasmid pOGIL6 was used to trans-
form yeast strain BJ2168. After cloning, individual
transformants were grown on in liquid culture, and
lysed after growth in induction conditions. An inducible
protein was produced by the transformed cells which
was of the predicted size for a TyP1-IL-6 fusion protein
product, and blotted with an anti-P1 rabbit antiserum
(Fig. 2). When purified by differential sucrose gradient
centrifugation, this fusion protein could be digested
with Factor Xa to yield a Mr 5 24 000 protein, puta-
tively ovine IL-6, as well as a Mr 5 50 000 band which
corresponds to P1 protein present as vlps. Further cen-
trifugation to remove remaining vlps allows the recov-
ery of the released IL-6 with a yield of c100 µg/litre of
culture, at a purity of about 90% as estimated by silver
stain staining of PAGE gels.
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Figure 1A. Primers used in cloning the ovine IL-6 cDNA.
054R and 056R were derived from regions of consensus between
murine and human genes, whilst 053R contains IL-6 sequence
derived from the bovine gene (B. Collins, personal communication)
and shows two changes from the sequence of the ovine gene in
Figure 1B. Non IL-6 sequences used in the expression construct are
underlined.
Figure 1B. Sequence of the coding region of ovine IL-6 cDNA.
The sequence of the PCR product of 054R and 056R was determined
from both strands of three clones. The complete protein coding
region is shown. Maturation of the protein leads to a probable
amino-terminus at position 29 (underlined).
Figure 2. Expression of rovIL-6 protein in yeast.
(A) Proteins from various stages of IL-6 purification were analysed
by electrophoresis on SDS-15% polyacrylamide gels, followed by
staining with Coomassie blue R. Lane M: marker proteins. Lane 1:
total proteins from a lysed control yeast expressing the TyP1 protein
from the plasmid pOGS41 after 16 h induction with galactose. Lane
2: total proteins from a yeast strain transfected with pOGIL-6 after
16 h induction with galactose. Lane 3: partially purified virus-like
particles of P1/IL-6 fusion protein from the 60% sucrose cushion
after the first centrifugation step. Lane 4: virus-like particles of
P1/IL-6 fusion protein with factor Xa added, prior to digestion. Lane
5: virus like particles after factor Xa cleavage. Lane 6: purified rov-
IL-6 after removal of vlp’s by centrifugation. This lane is a silver
stained preparation, from a different gel. (B) A western blot of a
similar gel (lanes 1–5) was probed with a polyclonal antiserum raised
against P1 protein.
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Biological  activity of rov IL-6
The purified material was used in two assays of 
IL-6 activity. B9 cells offer a highly sensitive prolifera-
tion assay for human and murine IL-6, although these
cells will also proliferate in the presence of murine (but
not human) IL-4. Proliferation assays were performed
using these cells and the yeast expressed rovIL-6 (Fig. 3).
This material was able to support proliferation of these
cells, but only relatively poorly, and at concentrations of
1–10 ng/ml and above, some four orders of magnitude
higher than the concentrations at which rhuIL-6 is active.
(In the assay shown, rhuIL-6 is already super-optimal 
for stimulation at 20 pg/ml. In other assays, optimal 
stimulation by rhuIL-6 was achieved in the range 0.1–1
pg/ml, in good agreement with the findings of other
authors for this cell line.8) Mixing rovIL-6 with rhuIL-6
did not affect proliferation to rhuIL-6, showing that there
was no toxicity from rovIL-6 (data not shown). P1 pro-
tein alone was unable to cause proliferation of B9 cells
at any concentration measured.
To measure the activity of rovIL-6 on ovine cells,
IL-6 was used to drive immunoglobulin production  by
peripheral blood mononuclear cells9 (Fig. 4). RovIL-6
at concentrations above 10 ng/ml was able to potenti-
ate total immunoglobulin production by these cells in
the presence of pokeweed mitogen (measured in an
ELISA assay) by anything from 2–8 fold in different
sheep. (Production of Ig in the absence of IL-6 varied
between 2 and 7 µg/ml.) These concentrations are com-
parable to those required to cause similar enhance-
ments of Ig production by rhuIL-6 acting on human
EBV transformed B-cells.16 The same ovine cell popu-
lations were much less responsive to a control protein
preparation consisting of the equivalent purification
fractions from a factor Xa digested P1 expressing yeast.
Nor were they sensitive to rhuIL-6 at these concentra-
tions (data not shown). This suggests that there is a par-
tial barrier in IL-6 recognition between sheep IL-6 and
mouse IL-6 receptors and between human IL-6 and
sheep IL-6 receptors which does not exist between
human IL-6 and mouse IL-6 receptors.
DISCUSSION 
Ovine recombinant IL-6 has been cloned and
expressed in a yeast based system. The sequence is iden-
tical to that reported very recently by Andrews et al.,10
although these authors did not express protein from
their gene. On Northern blotting the clone described in
the current study hybridizes to a rare transcript in sheep
alveolar macrophages of 1.26 kb. RT PCR experiments
showed that this manuscript was induced in the
macrophages by LPS stimulation in vitro. Induction of
the transcript occurs by 1 h post treatment, and con-
tinues for at least 3 h (data not shown).
The protein expressed in the current study is a pro-
protein, but it retains functional activity on ovine cells.
However, there is a partial species barrier between
ovine IL-6 and murine cells which is not present
between human IL-6 and murine cells, preventing
extensive proliferation of the B9 myeloma line in
response to the ovine molecule. Similarly, human IL-6
is not able to potentiate immunoglobulin synthesis by
ovine peripheral blood mononuclear cells. This type of
species barrier has been noted before in other species.
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Figure 3. Proliferative response of B9 cells to recombinant IL-6.
Medium control (d), rhuIL-6 (h) or rovIL-6 (j) was used to stimu-
late proliferation of the murine myeloma cell line B9 for 36 h. 3H-
Thymidine incorporation was measured over the next 5 h. Means
and ranges of incorporated counts are shown. Where no error bars
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Figure 4. Immunoglobulin production by peripheral blood lym-
phocytes in response to IL-6.
Ig secretion from 105 cells over a period of 7 days in culture was mea-
sured in a light chain capture ELISA as stated. Test samples in a vol-
ume of 100 µl were purified rovIL-6 or a control preparation of
supernatant after an insert-less P1vlp protein was digested with fac-
tor Xa and centrifuged. Means of Ig production and standard devia-
tions are shown: (j) effect of addition of rovIL-6 to cells; (h) effect
of addition of control preparation to cells.
Although human IL-6 will bind to the murine IL-6
receptor and activate murine IL-6 dependent cell lines,
murine IL-6 is unable to activate human cells in the
same way.11
IL-6 sequences are not extensively conserved
between species, but four cysteine residues forming
disulphide bridges at positions 72–78 and 101–111 are
conserved across the ovine protein as well as those of
other species.12 (These cysteines define a structural fam-
ily of cytokines including IL-2, IL-4, GM-CSF, G-CSF,
to which LIF and erythropoietin are more distantly
related.) The most closely conserved regions across
species, within the IL-6 gene, are within the leader
sequence and also between residues 68 and 126. These
residues also form the best conserved region between
the human and murine proteins and this region consti-
tutes parts of two alpha helices, two turns defined by
the cysteine bridges and a long loop, at least part of
which is required for interaction between IL-6 and the
IL-6 binding subunit of IL-6R.19
Most studies of IL-6 structure/activity relation-
ships have used site directed mutagenesis of human 
IL-6 and have concentrated on the important role of
the carboxyl end of the protein in receptor binding.13–16
Residues 176–183 of the human mature protein and 
two sets of periodically arranged leucines (positions
167, 174 and 181; and positions 151, 158, 165 of the
human sequence) have both been suggested to be
important in this regard.22 Of these leucines in 
the human sequence, only those at positions 167 and
174 have equivalents in the ovine sequence (positions
191 and 198 of the sequence in Fig. 2). That at position
181 (human) is not present in most other IL-6
sequences, and can be substituted with several other
residues without effect.23 However, the absence of the
other spaced set of leucines may be important in the
observed species barrier.
MATERIALS AND METHODS
Cloning and sequencing of ovine IL-6
Alveolar macrophages were obtained from gnotobiotic
Finn 3 Blackface sheep by alveolar lavage and red blood cells
removed by hypoosmotic shock as before.17 2 3 107 cells were
plated into plastic tissue culture bottles in Iscove’s serum free
medium and allowed to adhere for 24 h. Adherent cells (.90%
macrophages by non-specific esterase staining) were then stim-
ulated with 10 µg/ml LPS from Salmonella abortus equi for 4 h.
Total RNA was purified by the acidified guanidine thio-
cyanate method18 and used as a template for single stranded
cDNA synthesis using oligo dT primers and AMV reverse
transcriptase. Primers 054R and 056R for amplification of the
ovine IL-6 gene were selected from well conserved regions of
the 59 and 39 untranslated regions of the IL-6 gene in human
and mouse (Fig. 1A). The cDNA was amplified through 35
cycles using these primers and the buffer conditions of Ohara
and Gilbert.19 The product of PCR was purified by agarose
gel electrophoresis and electroelution. This product was lig-
ated directly into the phosphorylated cloning site of the plas-
mid pCR2 according to the manufacturer’s instructions
(Invitrogen, Ca., USA). Clones containing inserts were
sequenced on both strands using the di-deoxy nucleotide
chain termination method.
Construction of a ruminant IL-6 cassette
A primer was designed containing the 59 22 bases of a
ruminant IL-6 sequence (derived from an unpublished bovine
IL-6 sequence, B Collins, personal communication) attached
to a coagulation Factor Xa recognition site, a BamHI site and
a GC clamp (Fig. 1A). This primer (053R) was used in com-
bination with a second primer (159R) containing a GC clamp
and BamHI site attached to the antisense of the last 22 bases
of the ovine IL-6 structural sequence (up to and including the
stop codon) in a PCR using the same cDNA population as
before. The resulting product, after gel purification, was
digested with BamHI and cloned into the BamHI site of
pTZ18R (Pharmacia). A clone containing an insert of the
expected size was sequenced, and the insert cleaved out with
BamHI and purified by agarose gel electrophoresis. The insert
was ligated into the BamHI site of the yeast Ty expression
plasmid pOGS40. Plasmids containing the correct size of
insert were sequenced across the junctions between insert and
vector to determine the direction of cloning and make sure
that no frame shifts had occurred during cloning. A plasmid
pOGIL6 was selected for further work.
Expression and purification of IL-6 from yeast
The method used was essentially that of Gilmour et al.20
with modifications as published previously.21 Briefly, pOGIL6
was transfected into yeast BJ2168 by spheroplasting, plating
in regeneration agar (0.67% yeast nitrogen base; 1M sorbitol;
1% glucose; 3.0% Difco agar) and incubating at 30°C.
Colonies obtained, after re-streaking, were grown in liquid
culture. For inducible expression they were grown at 30°C for
48 h in YNB (0.67% yeast nitrogen base) containing 1% glu-
cose and 0.002% tryptophan, then induced for 16–24 h with
1% galactose 1 0.3% glucose and and tryptophan. Cells were
harvested, suspended in 10 mM Tris-HCl pH 7.4, 2 mM
EDTA, 140 mM NaCl containing protease inhibitors and
lysed by vortexing with acid washed glass beads. Supernatants
were spun at 10 000 3 g for 5 mins, the yeast debris discarded,
and the vlp containing suspension partially purified and con-
centrated by spinning at 30 000 3 g for 90 min onto a 60%
sucrose cushion. The interface and cushion material were dial-
ysed into 100 mM Tris/HCl pH 7.4, 10 mM CaCl2 containing
0.1% DOC (Na deoxycholate). Expressed protein was
released from the vlps by digestion with Factor Xa at a con-
centration of 1:50 w/w for 4 h at 25°C and further purified by
centrifugation at 40 000 3 g for 40 min to remove the P1, vlps
present post cleavage as well as any remaining yeast proteins.
Samples were dialysed into PBS and stored at 270°C.
Analysis of ovine IL-6 RNA and protein
Alveolar macrophages were plated in Iscoves medium
and stimulated with 10 µg/ml LPS for various times. Total
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RNA extracted using RNAzol B (Cinna Biotix) was analysed
by Northern blotting followed standard methods. For RT
PCR, cDNA was prepared from 1 µg total RNA, using the
method of Rolfs et al.22 Primers 053R and 159R were then
used in a 40 cycle PCR (otherwise as before) with 1/10 of the
cDNA sample. SDS polyacrylamide gel electrophoresis and
Western blots were as before.12
Cell proliferation assay
B9 cells, a murine IL-6-dependent hybridoma cell line,
were used in proliferation assays to measure the biological
activity of recombinant ovine IL-6 (rovIL-6). Proliferation
was measured according to the method of Aarden et al., 1987.23
4 3 103 B9 cells were incubated in duplicate wells with test
sample in RPMI1640, 10% foetal calf serum 100 units ml21
penicillin, 100 µg ml21 streptomycin, in 200 µl total volume
for 3 days at 37°C. They were then pulsed with 1 µCi 
3H-thymidine for 5 h, prior to harvesting, washing and scin-
tillation counting.
Total immunoglobulin production assay
Washed peripheral blood mononuclear cells 
(1 3 105) were incubated in 96-well flat-bottomed ELISA
plates in 200 µl RPMI1640 containing 2 mM glutamine, 5 3
1025M 2-mercaptoethanol, 200 µg/ml gentamycin, 10% fetal
calf serum, supplemented with pokeweed mitogen (Gibco
product 061-05360B, used at 1 in 10 000) and test samples as
stated in figure legends. Assays were performed in triplicate.
After 7 days in culture the supernatants were assayed in a cap-
ture ELISA for total immunoglobulin. Total Ig was measured
using a mouse anti-sheep Ig light chain monoclonal antibody,
VPM8,28 to coat ELISA plates as capture antibody, and a puri-
fied rabbit anti-sheep Ig antibody directly conjugated to
horse-radish peroxidase to develop (P. Bird, in preparation).
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